<p>The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Bayer AG’s finerenone (Kerendia™) for the treatment of adults with heart failure with left ventricular ejection fraction (LVEF) ≥40%, which includes those with mildly reduced or preserved ejection fraction. The recommendation is based on results from the Phase III FINEARTS-HF study, which demonstrated that finerenone significantly reduced the composite endpoint of cardiovascular death and total heart failure events compared to placebo in addition to standard therapy. The final decision from the European Commission is expected in the coming weeks. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on January 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

SBIO

Reuters

iShares Biotechnology ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

VG Health

First Trust NYSE Arca Biotech Index Fd

Bayer AG

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

iShares Global Healthcare

Bayer

EMA Panel Recommends Bayer’s Finerenone for Heart Failure with Preserved Ejection Fraction